A citation-based method for searching scientific literature

Yaogeng Wang, Rolf W Sparidans, Sander Potters, Maria C Lebre, Jos H Beijnen, Alfred H Schinkel. Pharmacol Res 2021
Times Cited: 2







List of co-cited articles
4 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Overcoming MET-Dependent Resistance to Selective RET Inhibition in Patients with RET Fusion-Positive Lung Cancer by Combining Selpercatinib with Crizotinib.
Ezra Y Rosen, Melissa L Johnson, Sarah E Clifford, Romel Somwar, Jennifer F Kherani, Jieun Son, Arrien A Bertram, Monika A Davare, Eric Gladstone, Elena V Ivanova,[...]. Clin Cancer Res 2021
35
100

Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry.
Oliver Gautschi, Julie Milia, Thomas Filleron, Juergen Wolf, David P Carbone, Dwight Owen, Ross Camidge, Vignhesh Narayanan, Robert C Doebele, Benjamin Besse,[...]. J Clin Oncol 2017
195
100

Advances in Targeting RET-Dependent Cancers.
Vivek Subbiah, Gilbert J Cote. Cancer Discov 2020
44
100

Efficacy of Selpercatinib in RET Fusion-Positive Non-Small-Cell Lung Cancer.
Alexander Drilon, Geoffrey R Oxnard, Daniel S W Tan, Herbert H F Loong, Melissa Johnson, Justin Gainor, Caroline E McCoach, Oliver Gautschi, Benjamin Besse, Byoung C Cho,[...]. N Engl J Med 2020
203
100

Breast cancer resistance protein (BCRP/ABCG2) and P-glycoprotein (P-gp/ABCB1) transport afatinib and restrict its oral availability and brain accumulation.
Stéphanie van Hoppe, Rolf W Sparidans, Els Wagenaar, Jos H Beijnen, Alfred H Schinkel. Pharmacol Res 2017
37
50

Tissue distribution and ontogeny of mouse organic anion transporting polypeptides (Oatps).
Xingguo Cheng, Jonathan Maher, Chuan Chen, Curtis D Klaassen. Drug Metab Dispos 2005
128
50



Targeting RET-rearranged lung cancers with multikinase inhibitors.
Joshua K Sabari, Evan D Siau, Alexander Drilon. Oncoscience 2017
13
50

Cabozantinib in progressive medullary thyroid cancer.
Rossella Elisei, Martin J Schlumberger, Stefan P Müller, Patrick Schöffski, Marcia S Brose, Manisha H Shah, Lisa Licitra, Barbara Jarzab, Viktor Medvedev, Michael C Kreissl,[...]. J Clin Oncol 2013
658
50

Identification of Driving ALK Fusion Genes and Genomic Landscape of Medullary Thyroid Cancer.
Jun Ho Ji, Young Lyun Oh, Mineui Hong, Jae Won Yun, Hyun-Woo Lee, DeokGeun Kim, Yongick Ji, Duk-Hwan Kim, Woong-Yang Park, Hyun-Tae Shin,[...]. PLoS Genet 2015
75
50

Cytochrome P-450 3A4: regulation and role in drug metabolism.
F P Guengerich. Annu Rev Pharmacol Toxicol 1999
927
50

Role of Organic Anion-Transporting Polypeptides (OATPs) in Cancer Therapy.
Nilay Thakkar, A Craig Lockhart, Wooin Lee. AAPS J 2015
64
50

The landscape of kinase fusions in cancer.
Nicolas Stransky, Ethan Cerami, Stefanie Schalm, Joseph L Kim, Christoph Lengauer. Nat Commun 2014
568
50

Cabozantinib in patients with advanced RET-rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial.
Alexander Drilon, Natasha Rekhtman, Maria Arcila, Lu Wang, Andy Ni, Melanie Albano, Martine Van Voorthuysen, Romel Somwar, Roger S Smith, Joseph Montecalvo,[...]. Lancet Oncol 2016
272
50

OATP1A/1B, CYP3A, ABCB1, and ABCG2 limit oral availability of the NTRK inhibitor larotrectinib, while ABCB1 and ABCG2 also restrict its brain accumulation.
Yaogeng Wang, Rolf W Sparidans, Wenlong Li, Maria C Lebre, Jos H Beijnen, Alfred H Schinkel. Br J Pharmacol 2020
9
50

P-glycoprotein and breast cancer resistance protein restrict brigatinib brain accumulation and toxicity, and, alongside CYP3A, limit its oral availability.
Wenlong Li, Rolf W Sparidans, Yaogeng Wang, Maria C Lebre, Jos H Beijnen, Alfred H Schinkel. Pharmacol Res 2018
18
50


Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer.
Razelle Kurzrock, Steven I Sherman, Douglas W Ball, Arlene A Forastiere, Roger B Cohen, Ranee Mehra, David G Pfister, Ezra E W Cohen, Linda Janisch, Forlisa Nauling,[...]. J Clin Oncol 2011
407
50

Clarithromycin is absorbed by an intestinal uptake mechanism that is sensitive to major inhibition by rifampicin: results of a short-term drug interaction study in foals.
Jette Peters, Karen Eggers, Stefan Oswald, Wiebke Block, Dieter Lütjohann, Marc Lämmer, Monica Venner, Werner Siegmund. Drug Metab Dispos 2012
21
50

Membrane transporters in drug development.
Kathleen M Giacomini, Shiew-Mei Huang, Donald J Tweedie, Leslie Z Benet, Kim L R Brouwer, Xiaoyan Chu, Amber Dahlin, Raymond Evers, Volker Fischer, Kathleen M Hillgren,[...]. Nat Rev Drug Discov 2010
50


Impact of OATP transporters on pharmacokinetics.
A Kalliokoski, M Niemi. Br J Pharmacol 2009
611
50

Structure and physiology of the RET receptor tyrosine kinase.
Carlos F Ibáñez. Cold Spring Harb Perspect Biol 2013
98
50

What do drug transporters really do?
Sanjay K Nigam. Nat Rev Drug Discov 2015
277
50

The superfamily of organic anion transporting polypeptides.
B Hagenbuch, P J Meier. Biochim Biophys Acta 2003
618
50

Complete Knockout of Endogenous Mdr1 (Abcb1) in MDCK Cells by CRISPR-Cas9.
Ivailo Simoff, Maria Karlgren, Maria Backlund, Anne-Christine Lindström, Fabienne Z Gaugaz, Pär Matsson, Per Artursson. J Pharm Sci 2016
39
50


Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial.
Samuel A Wells, Bruce G Robinson, Robert F Gagel, Henning Dralle, James A Fagin, Massimo Santoro, Eric Baudin, Rossella Elisei, Barbara Jarzab, James R Vasselli,[...]. J Clin Oncol 2012
849
50

Clinical significance of organic anion transporting polypeptides (OATPs) in drug disposition: their roles in hepatic clearance and intestinal absorption.
Yoshihisa Shitara, Kazuya Maeda, Kazuaki Ikejiri, Kenta Yoshida, Toshiharu Horie, Yuichi Sugiyama. Biopharm Drug Dispos 2013
264
50

RET Aberrations in Diverse Cancers: Next-Generation Sequencing of 4,871 Patients.
Shumei Kato, Vivek Subbiah, Erica Marchlik, Sheryl K Elkin, Jennifer L Carter, Razelle Kurzrock. Clin Cancer Res 2017
113
50

The RET receptor: function in development and dysfunction in congenital malformation.
S Manié, M Santoro, A Fusco, M Billaud. Trends Genet 2001
224
50

Frequency of Brain Metastases and Multikinase Inhibitor Outcomes in Patients With RET-Rearranged Lung Cancers.
Alexander Drilon, Jessica J Lin, Thomas Filleron, Ai Ni, Julie Milia, Isabella Bergagnini, Vaios Hatzoglou, Vamsidhar Velcheti, Michael Offin, Bob Li,[...]. J Thorac Oncol 2018
69
50

PKSolver: An add-in program for pharmacokinetic and pharmacodynamic data analysis in Microsoft Excel.
Yong Zhang, Meirong Huo, Jianping Zhou, Shaofei Xie. Comput Methods Programs Biomed 2010
50

Vandetanib in patients with previously treated RET-rearranged advanced non-small-cell lung cancer (LURET): an open-label, multicentre phase 2 trial.
Kiyotaka Yoh, Takashi Seto, Miyako Satouchi, Makoto Nishio, Noboru Yamamoto, Haruyasu Murakami, Naoyuki Nogami, Shingo Matsumoto, Takashi Kohno, Koji Tsuta,[...]. Lancet Respir Med 2017
200
50

Quantitative bioanalytical assay for the selective RET inhibitors selpercatinib and pralsetinib in mouse plasma and tissue homogenates using liquid chromatography-tandem mass spectrometry.
Rahime Şentürk, Yaogeng Wang, Alfred H Schinkel, Jos H Beijnen, Rolf W Sparidans. J Chromatogr B Analyt Technol Biomed Life Sci 2020
4
50

c-RET molecule in malignant melanoma from oncogenic RET-carrying transgenic mice and human cell lines.
Yuichiro Ohshima, Ichiro Yajima, Kozue Takeda, Machiko Iida, Mayuko Kumasaka, Yoshinari Matsumoto, Masashi Kato. PLoS One 2010
36
50

Efficacy of Selpercatinib in RET-Altered Thyroid Cancers.
Lori J Wirth, Eric Sherman, Bruce Robinson, Benjamin Solomon, Hyunseok Kang, Jochen Lorch, Francis Worden, Marcia Brose, Jyoti Patel, Sophie Leboulleux,[...]. N Engl J Med 2020
171
50

A secondary RET mutation in the activation loop conferring resistance to vandetanib.
Takashi Nakaoku, Takashi Kohno, Mitsugu Araki, Seiji Niho, Rakhee Chauhan, Phillip P Knowles, Katsuya Tsuchihara, Shingo Matsumoto, Yoko Shimada, Sachiyo Mimaki,[...]. Nat Commun 2018
52
50


Multiple endocrine neoplasia type 2 RET protooncogene database: repository of MEN2-associated RET sequence variation and reference for genotype/phenotype correlations.
Rebecca L Margraf, David K Crockett, Patti M F Krautscheid, Ryan Seamons, Fernanda R O Calderon, Carl T Wittwer, Rong Mao. Hum Mutat 2009
98
50

RET fusions in solid tumors.
Andrew Y Li, Michael G McCusker, Alessandro Russo, Katherine A Scilla, Allison Gittens, Katherine Arensmeyer, Ranee Mehra, Vincenzo Adamo, Christian Rolfo. Cancer Treat Rev 2019
76
50

RET inhibition in novel patient-derived models of RET-fusion positive lung adenocarcinoma reveals a role for MYC upregulation.
Takuo Hayashi, Igor Odintsov, Roger S Smith, Kota Ishizawa, Allan J W Liu, Lukas Delasos, Christopher Kurzatkowski, Huichun Tai, Eric Gladstone, Morana Vojnic,[...]. Dis Model Mech 2020
6
50

Antitumor Activity of RXDX-105 in Multiple Cancer Types with RET Rearrangements or Mutations.
Gang G Li, Romel Somwar, James Joseph, Roger S Smith, Takuo Hayashi, Leenus Martin, Aleksandra Franovic, Anni Schairer, Eric Martin, Gregory J Riely,[...]. Clin Cancer Res 2017
50
50


Catalog of 5' fusion partners in RET+ NSCLC Circa 2020.
Sai-Hong Ignatius Ou, Viola W Zhu. JTO Clin Res Rep 2020
5
50

KLIFS: a knowledge-based structural database to navigate kinase-ligand interaction space.
Oscar P J van Linden, Albert J Kooistra, Rob Leurs, Iwan J P de Esch, Chris de Graaf. J Med Chem 2014
165
50

Pralsetinib: First Approval.
Anthony Markham. Drugs 2020
31
50

RET Rearrangement as a Predictor of Unresponsiveness to Immunotherapy in Non-Small Cell Lung Cancer: Report of Two Cases with Review of the Literature.
Sara Baglivo, Vienna Ludovini, Riccardo Moretti, Guido Bellezza, Angelo Sidoni, Fausto Roila, Giulio Metro. Oncol Ther 2020
10
50

Pralsetinib: Treatment of metastatic RET fusion-positive non-small cell lung cancer.
Ly Nguyen, Shanada Monestime. Am J Health Syst Pharm 2022
1
100


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.